Drug Topics May 1, 2024
Pharmacists can help financial decision makers understand the value of biosimilar therapies.
Although biosimilar drugs are poised to save billions in health care spending, hesitancy remains around their uptake. In addition to provider and patient education, decision makers need to understand the financial implications of these therapies.
“Helping the administrative staff…understand the financial value of biosimilars to their institution is also a key area where pharmacists can really show value and show that there are opportunities that may be beyond what meets the eye for savings,” said Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health.
In the 2024 Cardinal Health Biosimilar Report,1 Gregory noted that US health care spending in 2022 reached $4.5 trillion, $252...
Today's Sponsors
Today's Sponsor